trial · primary record
Amivantamab
Carcinoma, Non-small-Cell Lung
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 520 |
| Primary completion | 2028-08-18 |
| Primary endpoint | All Cohorts Except Cohort 4: Objective Response Rate (ORR) Based on Investigator Assessment (INV) |
| Registry ID | NCT05498428 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:55.107Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05498428
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Amivantamab · compound